NEW YORK (GenomeWeb News) – BGI-Shenzhen today said that it has extended its offer to acquire Complete Genomics for $3.15 per share.

The offer, with a total deal value of nearly $118 million, was scheduled to expire at midnight tonight, New York City time. It has now been extended to midnight on Wednesday, Nov. 21.

According to BGI, as of the close of business yesterday, approximately 6,731,897 shares had been validly tendered and not withdrawn from the offer. Complete Genomics has roughly 34.3 million total shares outstanding.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.